Insights+ Key Biosimilars Events of June 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of June, Samsung Bioepis presented results of SB12…

BySenior EditorJuly 5, 2023

THOUGHTSPOT

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Shots:Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…

BySaurabh ChaubeyJune 6, 2023

THOUGHTSPOT

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Shots:In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysisLike any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…

BySenior EditorMay 1, 2023

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots:With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturingWhile major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…

BySenior EditorApril 13, 2023

TOP 20

Top 20 BioPharma Companies based on 2022 Total Revenue

Shots:Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies.Amidst all kinds of obstacles, many companies have sustained themselves to meet the market…

ByPrince GiriApril 12, 2023

TOP 20

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Shots:Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versionsLike every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…

ByPrince GiriMarch 29, 2023

TOP 20

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots:Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnershipTo tackle such scenarios, companies are cautious enough to make backup plans beforehand…

ByPrince GiriMarch 22, 2023

INSIGHTS+

Top Performing Drug of 2021 – Darzalex (March Edition)

Shots:The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March monthDarzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugsThe report summarizes the key features of Darzalex including revenue…

BySenior EditorMarch 21, 2023

INSIGHTS+

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots:The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots:The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6BIn the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

Insights+ Key Biosimilars Events of June 2023

Intelligent Automation in Pharmaceutical Industry (AI & ML)

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Top 20 BioPharma Companies based on 2022 Total Revenue

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Top Performing Drug of 2021 – Darzalex (March Edition)

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

PharmaShots’ Key Highlights of Fourth Quarter 2022

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter